Insmed Inc. (INSM)
International Markets and Insmed (INSM): A Deep Dive for Investors
Examine Insmed's (INSM) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Insmed's Q4 Loss Wider Than Expected, Sales In Line With Estimates
INSM posts wider-than-expected Q4 loss. It reiterates its 2025 sales outlook for Arikayce in the range of $405-$425 million.
Insmed Incorporated (INSM) Q4 2024 Earnings Call Transcript
Insmed Incorporated (INSM) Q4 2024 Earnings Call Transcript
Insmed (INSM) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Insmed (INSM) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Insmed (INSM) Reports Q4 Loss, Tops Revenue Estimates
Insmed (INSM) came out with a quarterly loss of $1.32 per share versus the Zacks Consensus Estimate of a loss of $1.15. This compares to loss of $1.28 per share a year ago.
Countdown to Insmed (INSM) Q4 Earnings: Wall Street Forecasts for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Insmed (INSM), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.
Insmed (INSM) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insmed: Priority Review For Brensocatib Cements (Limited) Upside Opportunity
Insmed's Arikayce, a treatment for MAC and NTM lung diseases, generated $93.4m in Q3 2023, with full-year revenue guidance of $340m-$360m. Brensocatib, Insmed's lead pipeline candidate for non-CF bronchiectasis, received FDA Priority Review with a target action date of August 12, 2025. This is a potential multi-billion dollar selling asset. Brensocatib's market potential is significant, with Wall Street analysts projecting peak annual revenues exceeding $5bn, bolstering Insmed's market cap of $14.45bn.
Insmed's NDA for Lung Disease Drug Gets FDA's Priority Review
The FDA accepts and grants priority review to INSM's NDA for brensocatib to treat patients with non-cystic fibrosis bronchiectasis. A decision is due on Aug. 12, 2025.
Insmed: PAH Treatment Advancement With 2nd Half 2025 Top-Line Data
Insmed Incorporated's ARIKAYCE, approved for MAC lung disease, achieved strong revenue growth in Q3 of 2024 and potential for expanded FDA approval, boosting its market opportunity. Brensocatib's NDA filing for bronchiectasis is expected in Q4 2024 and could lead to a U.S. launch by mid-2025. Top-line results from the phase 2b study, using TPIP for the treatment of patients with PAH, expected in the 2nd half of 2025.
Insmed (INSM) Reliance on International Sales: What Investors Need to Know
Review Insmed's (INSM) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Insmed's Q3 Loss Wider Than Expected, Sales In Line With Estimates
INSM posts wider-than-expected Q3 loss. The company plans to meet the FDA before 2024-end to discuss the possibility of an accelerated approval to expand Arikayce's label.
